GNNSF News and Press, Genscript Biotech Corp From 03/15/20

Deals and Financings Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson &am...

Deals and Financings HitGen, a Chengdu small molecule discovery company, has been approved for a $97 million IPO on Shanghai's new Science and Technology Innovation Board. HitGen has built a DNA-encoded library that contains nearly 400 billion novel, diverse, drug-like small molecule and m...